Home
→
Browsing by Author

Browsing by Author "Borghaei H."

Now showing items 1-6 of 6

Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)

Bodor J.; Boumber Y.; Borghaei H. (2019)

© 2019 American Cancer Society The emergence of immunotherapy has dramatically changed how non–small-cell lung cancer is treated, and longer survival is now possible for some patients, even those with advanced disease. ...
Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer

Beck T.; Boumber Y.; Aggarwal C.; Pei J.; Thrash-Bingham C.; Fittipaldi P.; Vlasenkova R.; Rao C.; Borghaei H.; Cristofanilli M.; Mehra R.; Serebriiskii I.; Alpaugh R. (2019)

© 2019 The Author(s). Background: Circulating tumor cells (CTC) and plasma cell-free RNA (cfRNA) can serve as biomarkers for prognosis and treatment response in lung cancer. One barrier to the selected or routine use of ...
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors

Arora S.; Velichinskii R.; Lesh R.; Ali U.; Kubiak M.; Bansal P.; Borghaei H.; Edelman M.; Boumber Y. (2019)

© 2019, The Author(s). In the last few years, immunotherapy has transformed the way we treat solid tumors, including melanoma, lung, head neck, breast, renal, and bladder cancers. Durable responses and long-term survival ...
Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC)

Makhov P.; Bychkov I.; Faezov B.; Deneka A.; Kudinov A.; Nicolas E.; Brebion R.; Avril E.; Cai K.Q.; Kharin L.V.; Voloshin M.; Frantsiyants E.; Karnaukhov N.; Kit O.I.; Topchu I.; Fazliyeva R.; Nikonova A.S.; Serebriiskii I.G.; Borghaei H.; Edelman M.; Dulaimi E.; Golemis E.A.; Boumber Y. (2021)

Non-small cell lung cancer (NSCLC) has limited treatment options. Expression of the RNA-binding protein (RBP) Musashi-2 (MSI2) is elevated in a subset of non-small cell lung cancer (NSCLC) tumors upon progression, and ...
Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis

Kudinov A.; Deneka A.; Nikonova A.; Beck T.; Ahn Y.; Liu X.; Martinez C.; Schultz F.; Reynolds S.; Yang D.; Cai K.; Yaghmour K.; Baker K.; Egleston B.; Nicolas E.; Chikwem A.; Andrianov G.; Singh S.; Borghaei H.; Serebriiskii I.; Gibbons D.; Kurie J.; Golemis E.; Boumber Y. (2016)

© 2016, National Academy of Sciences. All rights reserved.Non-small cell lung cancer (NSCLC) has a 5-y survival rate of ∼16%, with most deaths associated with uncontrolled metastasis. We screened for stem cell identity-related ...
Targeting the epidermal growth factor receptor in egfr-mutated lung cancer: Current and emerging therapies

Khaddour K.; Jonna S.; Deneka A.; Patel J.D.; Abazeed M.E.; Golemis E.; Borghaei H.; Boumber Y. (2021)

Epidermal growth factor receptor-targeting tyrosine kinase inhibitors (EGFR TKIs) are the standard of care for patients with EGFR-mutated metastatic lung cancer. While EGFR TKIs have initially high response rates, inherent ...

Now showing items 1-6 of 6

Search DSpace

Advanced Search

Browse

All of Kazan Federal University Digital Repository

Browsing by Author "Borghaei H."

Browsing by Author "Borghaei H."

Search DSpace

Browse

All of Kazan Federal University Digital Repository

My Account